JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis (JADE TEEN)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy and Safety of PF-04965842 Co-Administered With Background Medicated Topical Therapy in Adolescent Participants 12 to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Category & Conditions: Skin Diseases and Conditions
Medicine: abrocitinib (PF-04965842)
ClinicalTrials.gov Identifier (NCT): NCT03796676
Protocol ID: B7451036
PrintDownloadOpen Plain Language Summary Result: Click here